Cervantes et al developed a new prognostic score for patients with primary myelofibrosis. This can help to identify patients who may benefit from more aggressive management. The work was based on a study by the International Working Group for Myelofibrosis Research and Treatment (IWGMRT).
NOTE: Some of the prognostic factors overlap with previous prognostic scores reported in 28.13.05 and 28.13.19.
Parameters at diagnosis:
(1) age in years
(2) constitutional symptoms (unexplained fever, excessive sweating for > 1 month, and/or weight loss > 10% = B symptoms for malignant lymphoma)
(3) hemoglobin in g/dL
(4) white blood cell count
(5) percent blasts in the peripheral blood
|
Parameter |
Finding |
Points |
|
age in years |
<= 65 years of age |
0 |
|
|
> 65 years of age |
1 |
|
constitutional symptoms |
absent |
0 |
|
|
present |
1 |
|
hemoglobin |
>= 10 g/dL |
0 |
|
|
< 10 g/dL |
1 |
|
white blood cell count |
<= 25,000 per µL |
0 |
|
|
> 25,000 per µL |
1 |
|
percent blasts |
<= 1% |
0 |
|
|
> 1% |
1 |
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
• The higher the score the worse the patient's prognosis.
• Cytogenetic abnormalities were associated with anemia. Their presence influenced patients in the intermediate groups but not in the low or high risk groups.
|
Total Score |
Risk Group |
Median Survival |
|
0 |
low |
135 months |
|
1 |
intermediate-1 |
95 months |
|
2 |
intermediate-2 |
48 months |
|
3 to 5 |
high |
27 months |
Specialty: Hematology Oncology
ICD-10: ,
